Onconetix (ONCO)
Prostate-cancer diagnostics developer centered on the Proclarix blood test.
Something off on this page? Send us feedback.
Sells the Proclarix blood test in Europe and earns ancillary revenue from biomarker-development services and licensing, while Labcorp controls its U.S. development and commercialization path.
Sells Proclarix, a blood-based prostate-cancer test that combines paired protein-biomarker assays, PSA measurements, age, and a risk-score algorithm to aid evaluation after an indeterminate PSA result. Its wholly owned Swiss subsidiary, Proteomedix, sells test kits to laboratories, hospitals, medical centers, end users, and distributors in Europe, where the product remains in market development and is not reimbursed.
Provides biomarker discovery, assay design, and assay-development work under statements of work, while separately licensing intellectual property and biological materials related to cancer testing.
Operates through laboratory, distributor, supplier, and research partners: Labcorp holds exclusive U.S. rights while validation remains under way. The business has no manufacturing facilities; European sales depend on maintaining Class C IVDR certification, and core prostate-cancer biomarker rights are licensed from ETH Zurich and the State Hospital of St. Gallen.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.9M · Total debt $187.1K · Total assets $16.4M · Shareholders' equity $13.5M
- Revenue
- $17.1K
- Operating income
- −$2.7M
- Net income
- −$2.9M
No dividends on record.
| Institutions5 holders · as of Mar 31, 2026 | 0.04% | 1.7K shares | |
| Insiders8 holders · as of Aug 19, 2025 | 0.01% | 356 shares | |
| Strategic holders3 holders · as of Jul 27, 2026 | 5.89% | 232.5K shares | |
| Otherremainder | 94.06% | 3.71M shares |
3.95M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (3.95M in the company's Sep 3, 2026 report, 3.58M elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Keystone Capital Partners, LLCStrategic | 5.67% | 223,717 | 13Gfiled Jul 27, 2026 ↗ |
Altos Venture AGStrategic10 percent owner | 0.14% | 5,465 | Form 4filed Jul 16, 2025 ↗ |
HRT Financial LPStrategic10 percent owner | 0.09% | 3,365 | Form 4filed Apr 22, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.03% | 11,854 | 13Fas of Mar 31, 2026 |
Citigroup IncInstitution | 0.00% | 1,717 | 13Fas of Mar 31, 2026 |
| See all 18 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 21, 2026 | HRT Financial LP | 10 percent owner | −49,710 | $0.6900 |
| Apr 20, 2026 | HRT Financial LP | 10 percent owner | −94,462 | $0.7500 |
| Apr 16, 2026 | HRT Financial LP | 10 percent owner | −53,867 | $0.7300 |
| Apr 17, 2026 | HRT Financial LP | 10 percent owner | +34,636 | $0.7300 |
| Apr 14, 2026 | HRT Financial LP | 10 percent owner | +74,350 | $0.7700 |
- MDxHealth
Two urine tests target the elevated-PSA biopsy decision.
- OPKO Health
4Kscore is a multi-marker blood alternative before biopsy.
- Danaher
phi is a blood-test alternative for biopsy decisions.
- Abbott
Free-PSA assays anchor the standard PSA triage pathway.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Onconetix | $0.7030 | +2.63% | $2.4M | — | — | 3.7 | −83.9% |
| MDxHealth | $0.7121 | −1.14% | $36.5M | — | — | 0.4 | +2.3% |
| OPKO Health | $1.69 | −0.29% | $1.26B | — | — | 2.1 | +4.3% |
| Danaher | $209.00 | −0.43% | $147.59B | 37.3 | 23.6 | 5.9 | +5.5% |
| Abbott | $110.50 | +0.04% | $191.19B | 35.5 | 19.0 | 4.1 | +13.0% |
| Median | 36.4 | 21.3 | 3.1 | +4.9% |